SWE
Toggle navigation
English
Svenska
About Us
The Company
Board & Management
Scientific Advisory Board
Scientific Publications
Events & Mediawatch
Contact Us
Diabetes
Products
Clinical Trials
Investors
Investor Relations
CEO Comments
Corporate Governance
Press Releases
Financial Reports
Skip Navigation Links
Home
»
Investors
»
Press Releases
2020
2019
2018
2017
2016
2015
2014
2013
Former Diamyd Medical
Data pager
Data pager
1
2
3
Show:
PageSizeComboBox
select
10
20
50
100
150
3 pages
Press Releases
Data pager
Data pager
1
2
3
Show:
PageSizeComboBox
select
10
20
50
100
150
3 pages
10/12/2020
Financial and operational update about the diabetes vaccine Diamyd
®
10/7/2020
Year-End Report 19/20
9/16/2020
Diamyd Medical invites to a webcast presentation on September 17 on the results from DIAGNODE-2
9/15/2020
Diamyd Medical has received USD 13.9 million in connection with its divestment in Companion Medical
9/14/2020
Phase IIb topline results demonstrate a significant treatment effect of Diamyd
®
in a previously identified genetic subgroup of individuals with type 1 diabetes
9/1/2020
Analyses of prevention trials and intralymphatic pilot trial with the diabetes vaccine Diamyd
®
support a positive trend in genetically defined subgroups of type 1 diabetes
8/27/2020
Diamyd Medical updates on DIAGNODE-2 and upcoming Phase III trial with the diabetes vaccine Diamyd
®
8/24/2020
Clinical trial with Remygen
®
is expanded to evaluate prevention of hypoglycaemia
8/11/2020
Medtronic announces plans to aquire Companion Medical
8/5/2020
Diabetologia publishes results highlighting efficacy of the diabetes vaccine Diamyd
®
in genetically defined subgroups of type 1 diabetes
Order GAD for preclinical research
ORDER
©
Privacy Policy
|
Cookie Policy
Share This Page
select
Facebook
Twitter
LinkedIn
Google Plus
Pinterest
Tumblr
StumbleUpon
Blogger
MySpace
Digg
Reddit
Email
GAD PRODUCTS
Order GAD for preclinical research